EU Relapsing-Remitting MS Trials Should Have Active Controls - CPMP
Executive Summary
EU pivotal trials in relapsing-remitting multiple sclerosis should be structured as "active control parallel" studies, according to a guideline issued by the Committee for Proprietary Medicinal Products July 28.